ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson's Study

Aquinox Pharmaceuticals Inc. (AQXP: Quote) has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis.

The trial, dubbed KINSHIP, designed to enroll about 50 adult patients with mild to moderate atopic dermatitis is being conducted at clinical research centers in Canada.

AQXP closed Tuesday's trading 6.46% higher at $7.25.

ARIAD Pharmaceuticals Inc. (ARIA: Quote) has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries.

The seven countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. The commercial launches of Iclusig in these Central and Eastern European countries are expected to begin in 2015.

With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe.

Net product revenues from sales of Iclusig were $14.5 million for the quarter ended September 30, 2014, an increase of 22% from the second quarter of 2014.

ARIA closed Tuesday's trading at $6.82, down 1.23%. In after-hours, the stock was up 1.25% at $6.90.

Idera Pharmaceuticals Inc.'s (IDRA: Quote) drug candidate IMO-8400 has been granted orphan drug designation by FDA for the treatment of Waldenstrm's macroglobulinemia, a type of non-Hodgkin lymphoma.

IMO-8400 is currently under a phase 1/2 clinical trial in patients with Waldenstrm's macroglobulinemia who have a history of relapse or failure to respond to one or more prior therapies. The company expects final 24-week safety and clinical activity data from the trial in the second half of 2015.

More here:
ARIA Widens Sales Turf, NRX Skips A Beat, NDRM Triples On Parkinson's Study